Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Bitcoin ETF (BITO) vs CVS Health Corp (CVS) Price & Performance

ProShares Bitcoin ETFTrade
CVS Health CorpTrade

Price performance (Past 24H)

Key statistics

ProShares Bitcoin ETF vs CVS Health Corp — how do they compare? ProShares Bitcoin ETF trades at $8.59, while CVS Health Corp trades at $93.49 (market cap $122.36B). The key difference: CVS Health Corp pays a 2.78% dividend while ProShares Bitcoin ETF pays none, and CVS Health Corp is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

BITOCVS
Sector
Crypto-linkedHealth
52-Week High
$22.27$110.60
52-Week Low
$7.98$64.88
Market Cap
$122.36B
Enterprise Value
$184.71B
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Bitcoin ETF

BITO trades at $8.79, up 1.03% with a bullish technical signal from moving averages. The ETF maintains a consistent dividend distribution pattern with recent $0.01 payouts. Technical indicators show neutral oscillators but overall positive momentum, with support and resistance clustered around $9. The fund's performance reflects ongoing investor interest in Bitcoin exposure vehicles despite market volatility.

BITO faces structural challenges with higher fees impacting long-term returns compared to spot Bitcoin ETFs. Recent analyst coverage highlights tactical utility but questions buy-and-hold suitability. The fund's correlation breakdown with high-beta equities and persistent crypto market headwinds present significant risk factors for investors seeking sustained growth.

CVS Health Corp

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Bitcoin ETF

BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.

Read more on BITO

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS